VM26-induced changes in hepatic intermediary metabolism of mice.
D000818:Animals; D001786:Blood Glucose; D004317:Doxorubicin / Q000009:adverse effects; D004357:Drug Synergism; D005260:Female; D005947:Glucose / Q000378:metabolism; D006600:Hexosephosphates / Q000378:metabolism; D066298:In Vitro Techniques; D007523:Isocitrates / Q000378:metabolism; D007656:Ketoglutaric Acids / Q000378:metabolism; D007939:Leukemia L1210 / Q000188:drug therapy; D008099:Liver / Q000187:drug effects* / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D008930:Mitochondria, Liver / Q000187:drug effects / Q000378:metabolism; D010101:Oxygen Consumption; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D013386:Succinates / Q000378:metabolism; D013713:Teniposide / Q000008:administration & dosage / Q000494:pharmacology*
D001786:Blood Glucose; D006600:Hexosephosphates; D007523:Isocitrates; D007656:Ketoglutaric Acids; D013386:Succinates; D004317:Doxorubicin; D013713:Teniposide; D005947:Glucose; D011034:Podophyllotoxin